123 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34873089 | Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. | 2022 Mar 15 | 1 |
2 | 35099526 | Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. | 2022 Mar 1 | 1 |
3 | 35115810 | The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics. | 2022 | 2 |
4 | 35194103 | CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function. | 2022 Feb 22 | 1 |
5 | 35235559 | Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya. | 2022 | 2 |
6 | 35512066 | The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana. | 2022 Apr 29 | 1 |
7 | 32667979 | Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens. | 2021 May 18 | 1 |
8 | 32815870 | Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. | 2021 Jan | 1 |
9 | 32829410 | Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. | 2021 Oct 5 | 5 |
10 | 32909316 | Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. | 2021 Apr | 1 |
11 | 32960272 | CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. | 2021 Dec 6 | 4 |
12 | 33336382 | Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2. | 2021 Jun | 1 |
13 | 33599403 | Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population. | 2021 Mar | 1 |
14 | 33758532 | Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana. | 2021 | 3 |
15 | 33833550 | Erratum: Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]. | 2021 | 1 |
16 | 33872945 | Identification of miRNAs that regulate human CYP2B6 expression. | 2021 Jun | 2 |
17 | 34093191 | Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy. | 2021 | 2 |
18 | 34115651 | Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. | 2021 Oct 1 | 3 |
19 | 34415664 | Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. | 2021 Nov | 1 |
20 | 34474119 | Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults. | 2021 Dec 1 | 6 |
21 | 34882770 | Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS). | 2021 Nov 19 | 2 |
22 | 34945777 | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. | 2021 Dec 5 | 2 |
23 | 31628422 | Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. | 2020 Apr | 5 |
24 | 32106141 | Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. | 2020 Apr | 6 |
25 | 32377759 | Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6? | 2020 Aug | 1 |
26 | 32451120 | Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. | 2020 Jul | 4 |
27 | 32838647 | Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. | 2020 Aug | 1 |
28 | 33355828 | Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy. | 2020 Dec | 3 |
29 | 30535366 | Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. | 2019 Mar 1 | 1 |
30 | 31006110 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. | 2019 Oct | 3 |
31 | 31241542 | Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. | 2019 Aug 1 | 2 |
32 | 31243456 | Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. | 2019 Sep 1 | 1 |
33 | 31299074 | Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. | 2019 Oct 1 | 2 |
34 | 31324697 | Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. | 2019 Oct | 20 |
35 | 29629676 | A proposed management algorithm for late-onset efavirenz neurotoxicity. | 2018 Mar 28 | 2 |
36 | 29635009 | The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy. | 2018 Jul 1 | 1 |
37 | 29636682 | Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz. | 2018 | 1 |
38 | 29855606 | Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana. | 2018 Sep | 1 |
39 | 29868865 | Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. | 2018 Sep 1 | 1 |
40 | 30201214 | Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation. | 2018 Oct | 4 |
41 | 27799204 | Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. | 2017 Jan | 1 |
42 | 28403028 | Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. | 2017 Jul | 1 |
43 | 28481785 | Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana. | 2017 Aug 1 | 2 |
44 | 28559276 | Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. | 2017 Aug | 1 |
45 | 28718515 | Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. | 2017 Sep | 1 |
46 | 26553012 | In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. | 2016 Jan | 3 |
47 | 26655325 | CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women. | 2016 Jun | 2 |
48 | 26831894 | Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. | 2016 Feb 2 | 1 |
49 | 26891286 | Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings. | 2016 Feb 16 | 2 |
50 | 27045425 | CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. | 2016 Apr | 2 |